Transformative breakthroughs, biotech developments, digital therapeutics, and healthcare leadership.
U.S. employers are preparing for another year of steep healthcare cost growth, with spending projected to rise by 9.5% in 2027. Higher medical utilization, chronic disease, expensive medicines and increasingly costly claims are forcing companies to reconsider how they finance and structure employee health benefits.
Rising healthcare costs are forcing U.S. employers to reconsider coverage of GLP-1 drugs for weight management. The debate is increasingly about whether the high upfront cost of these medicines can be justified by measurable long-term health and financial benefits.
Cancer has become the leading condition driving employer healthcare costs in the United States, as rising diagnoses, expensive treatments and increasingly complex care put pressure on corporate benefit budgets. Employers are responding by placing greater emphasis on prevention, early detection, care navigation and higher-value treatment.
Rising premiums, deductibles, prescription costs and other out-of-pocket expenses are prompting more Americans to postpone medical care. The consequences extend beyond household finances, potentially affecting health outcomes, employers, productivity and the wider U.S. economy.
Prescription drug prices are showing signs of moderation in parts of the U.S. market, but lower prices do not necessarily translate into lower healthcare spending. Greater medicine use, expensive new therapies, rebates, insurance design and government price negotiations are reshaping who pays and who benefits.
Employer-sponsored healthcare is becoming a more consequential business cost as medical prices, prescription spending and demand for complex care rise. Companies are increasingly balancing benefit affordability and employee retention against pressure to control compensation costs and protect margins.
Telehealth has moved from pandemic-era workaround to a permanent part of American healthcare, but its economics remain unsettled. Hospitals are increasingly weighing the access and efficiency benefits of virtual care against reimbursement gaps, technology costs and already-thin operating margins.
Rising drug expenses are putting another strain on U.S. hospitals already managing higher labor, supply and administrative costs. The challenge is not simply the price of individual medicines, but the growing complexity of specialty therapies, purchasing arrangements, supply chains and reimbursement.
The U.S. drug market is becoming more efficient in some areas as generics and biosimilars expand, but specialty medicines are changing the economics of healthcare. For employers, insurers and hospitals, the challenge is increasingly how to finance high-value treatments without allowing a relatively small number of expensive therapies to distort overall healthcare costs.
Rising medical, pharmacy and specialty-treatment costs are putting renewed pressure on the U.S. employer-sponsored health system. As companies try to protect benefits while controlling spending, healthcare is increasingly becoming a question of workforce economics, productivity and corporate strategy.